Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry.
DISCUSSION: Our pilot data indicate that dabigatran appears to be safe for secondary stroke prevention during the first year of implementation of this therapy. However, high cost may limit the long-term treatment of AF patients with dabigatran, leading to early discontinuation.
PMID: 24790645 [PubMed - as supplied by publisher]
Source: Adv Data - Category: Epidemiology Authors: Tsivgoulis G, Krogias C, Sands KA, Sharma VK, Katsanos AH, Vadikolias K, Papageorgiou SG, Heliopoulos I, Shiue H, Mitsoglou A, Liantinioti C, Athanasiadis D, Giannopoulos S, Piperidou C, Voumvourakis K, Alexandrov AV Tags: Ther Adv Neurol Disord Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Congestive Heart Failure | Diabetes | Diabetes Mellitus | Dyspepsia | Endocrinology | Epidemiology | Gastroenterology | Heart | Heart Attack | Heart Failure | Hemorrhagic Stroke | Hospitals | Hypertension | Ischemic Stroke | Neurology | Pradaxa | Stroke | Study